4+ day, 11+ hour ago   (474+ words) A comprehensive genomic profiling study involving more than 13,000 patients has shown that targetable G12C mutations in the KRAS oncogene are rare in genitourinary cancers, potentially limiting the role of routine testing and targeted treatment in these malignancies. KRAS G12C accounts for approximately…...

4+ day, 11+ hour ago   (321+ words) European researchers have proposed a biomarker-based treatment algorithm for patients with mantle cell lymphoma that could move treatment decisions beyond age and transplant eligibility toward individualized strategies based on disease biology and treatment response. The call for a change to…...

1+ week, 2+ day ago   (450+ words) Reactive oxygen species are usually cast as the villains in cancer, capable of damaging DNA and promoting tumor growth. But new research shows that cancer-fighting T cells need small amounts of these molecules—and tumors may exploit that dependence to…...

1+ week, 5+ day ago   (443+ words) Two recent clinical readouts highlight both the promise and limitations of therapeutic cancer vaccines. The divergent outcomes sharpen a key question for the field: Is generating tumor-specific immunity enough, or must cancer vaccines also create conditions in which that immunity…...

2+ week, 4+ day ago   (435+ words) Research from the Karolinska Institute in Sweden shows assessing whether breast cancer tumors are estrogen receptor (ER) positive or not is more accurately measured as a spectrum rather than just classifying them as positive or negative. The researchers used a…...

2+ week, 4+ day ago   (246+ words) “What we are doing is developing a personalized but off-the-shelf cellular immunotherapy for cancer,” William V. Williams, MD, told Inside Precision Medicine. Williams is president and chief executive officer of BriaCell Bria-MEL+ is a cell-based therapeutic cancer vaccine designed to…...